Last reviewed · How we verify
Recombinant SARS-CoV-2 Ad5 vectored vaccine
The Recombinant SARS-CoV-2 Ad5 vectored vaccine, developed by the Jiangsu Province Centers for Disease Control and Prevention, is currently marketed but lacks detailed revenue figures. A key strength is its key composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the lack of detailed clinical trial results and primary indication data, which may limit its competitive positioning against other vaccines.
At a glance
| Generic name | Recombinant SARS-CoV-2 Ad5 vectored vaccine |
|---|---|
| Also known as | Ad5-nCoV |
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IH Convidecia as Second Booster Dose Against Breakthrough Infections (PHASE3)
- A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults (PHASE1)
- Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults (PHASE4)
- Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults (PHASE4)
- Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine (PHASE4)
- Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |